Jamie L. Fowler

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort.

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort.

Journal: EBioMedicine

Published: March 26, 2025

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Journal: Clinical and experimental immunology

Published: November 01, 2022

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 18, 2022

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Journal: Nature medicine

Published: December 24, 2021

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Journal: JCI insight

Published: December 08, 2021

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Journal: Lancet (London, England)

Published: June 24, 2021

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Journal: Nature medicine

Published: May 22, 2021

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Journal: The lancet. HIV

Published: April 19, 2021

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Journal: Nature medicine

Published: October 28, 2020

Presentation and treatment of anterior cervical hyperostosis.

Presentation and treatment of anterior cervical hyperostosis.

Journal: Annals of the Royal College of Surgeons of England

Published: August 15, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026